SCHEMBL20134826

SCHEMBL20134826

CC(C)C1(c2ccc(C(=O)N3CCC(c4nnc(-c5ccc(F)cc5)o4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.46
TP53 P04637 2/20 0.44
TNKS O95271 3/20 0.42
PARP1 P09874 2/20 0.42
PARP2 Q9UGN5 1/20 0.42
HTR2B P41595 1/20 0.41
HDAC3 O15379 1/20 0.41
CYP2C9 P11712 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.40
KMT2A Q03164 1/20 0.39
HSD11B1 P28845 6/20 0.38
TNKS2 Q9H2K2 1/20 0.38
NPC1 O15118 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134822 1.00 MAPT (0.46) MAPTTP53TNKSPARP1PARP2
SCHEMBL20135446 0.93 TP53 (0.51) MAPTTP53TNKSPARP1PARP2
SCHEMBL20135447 0.93 TP53 (0.51) MAPTTP53TNKSPARP1PARP2
SCHEMBL20134936 0.92 TNKS (0.42) MAPTTP53TNKSPARP1PARP2
SCHEMBL20134938 0.92 TNKS (0.42) MAPTTP53TNKSPARP1PARP2
SCHEMBL20135252 0.92 TP53 (0.47) MAPTTP53TNKSPARP1PARP2
SCHEMBL20135255 0.92 TP53 (0.47) MAPTTP53TNKSPARP1PARP2
SCHEMBL20134783 0.85 TP53 (0.53) MAPTTP53TNKSPARP1PARP2
SCHEMBL20134784 0.85 TP53 (0.53) MAPTTP53TNKSPARP1PARP2
SCHEMBL20135474 0.81 TP53 (0.41) MAPTTP53TNKSPARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MAPT 4505/4885TP53 4082/4885TNKS 1975/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MAPT 4265/4885TP53 3806/4885TNKS 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.